Cystic Fibrosis Foundation Otolaryngology Care Multidisciplinary Consensus Recommendations
International Forum of Allergy & Rhinology
Kimple, A. J., Senior, B. A., et al. (2022).
International Forum of Allergy & Rhinology, 12(9), 1089-1103.
This guideline provides recommendations regarding otolaryngologic care for individuals with cystic fibrosis, with further recommendations for management of hearing loss and dysphonia. The intended audience for this guideline is otolaryngologists and other healthcare providers assisting in the assessment and treatment of disorders commonly associated with cystic fibrosis.
Cystic Fibrosis Foundation
<div>Baseline hearing evaluations for ototoxic monitoring is recommended for all children and adults with cystic fibrosis (CF) in anticipation of receiving ototoxic medications. Ototoxic monitoring should then be conducted annually for the individuals with CF who are exposed to ototoxic medications, or after each course of intravenous ototoxic medications for individuals with a confirmed history of hearing loss. Individuals with CF without a confirmed history of hearing loss should be given the option of ototoxic monitoring after each course of intravenous ototoxic medications.</div>
<div>Voice evaluation and management should be provided to all adults and children with cystic fibrosis resulting in dysphonia.</div>
